Comparative Pharmacology
Head-to-head clinical analysis: LOARGYS versus MODICON 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOARGYS versus MODICON 28.
LOARGYS vs MODICON 28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces changes in cervical mucus and endometrium, impeding sperm penetration and implantation.
100 mg orally twice daily.
One tablet orally once daily, each tablet containing 0.035 mg ethinyl estradiol and 0.4 mg norethindrone, taken at the same time each day for 21 days followed by 7 days of placebo tablets.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours (prolonged in renal impairment).
Terminal elimination half-life: 13-19 hours (mean 16 hours) for norethindrone; steady state achieved within 5-7 days.
Primarily renal (70-80% unchanged; 10-15% as metabolites); biliary/fecal (5-10%).
Renal: 50-60% as metabolites, fecal: 40-50% as metabolites, with enterohepatic circulation; less than 1% unchanged in urine.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive